We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+31.06%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$4.93B
AUM Growth
+$243M
Cap. Flow
-$263M
Cap. Flow %
-5.34%
Top 10 Hldgs %
50.68%
Holding
90
New
9
Increased
18
Reduced
10
Closed
20

Top Buys

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$113M
2
ACRV icon
Acrivon Therapeutics
ACRV
+$61.1M
3
VOR icon
Vor Biopharma
VOR
+$57.5M
4
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$53.5M
5
PCVX icon
Vaxcyte
PCVX
+$50.1M

Top Sells

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$180M
2
BIIB icon
Biogen
BIIB
+$114M
3
RLMD icon
Relmada Therapeutics
RLMD
+$74M
4
ASND icon
Ascendis Pharma A/S
ASND
+$70.9M
5
THRD
Third Harmonic Bio
THRD
+$49.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
2 Financials 0.51%
3 Miscellaneous 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
51
EyePoint Inc
EYPT
$316M
$11.8M 0.24%
3,370,506
– –
ARYE
52
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$10.1M 0.2%
1,000,000
– –
HOWL icon
53
Werewolf Therapeutics
HOWL
$47.6M
$8.8M 0.18%
4,291,881
– –
WHWK
54
Whitehawk Therapeutics
WHWK
$233M
$7.57M 0.15%
590,218
– –
CNCE
55
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$6.36M 0.13%
1,088,296
– –
OBIO icon
56
Orchestra BioMed
OBIO
$363M
$6.09M 0.12%
610,283
– –
CNTB
57
Connect Biopharma Holdings
CNTB
$73.7M
$6.07M 0.12%
6,991,003
– –
LONA
58
LeonaBio Inc
LONA
$68.2M
$5.96M 0.12%
188,130
+330
+0.2% +$10.4K
STSA
59
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$5.32M 0.11%
5,914,252
– –
CVRX icon
60
CVRx
CVRX
$79.9M
$5.05M 0.1%
275,000
– –
BDTX icon
61
Black Diamond Therapeutics
BDTX
$113M
$4.66M 0.09%
2,589,904
– –
DBVT
62
DBV Technologies
DBVT
$739M
$3M 0.06%
195,896
-176,578
-47% -$2.6M
IOBT
63
DELISTED
IO Biotech
IOBT
$2.59M 0.05%
1,127,260
-730,495
-39% -$1.93M
THRD
64
DELISTED
Third Harmonic Bio
THRD
$2.3M 0.05%
534,687
-2,941,000
-85% -$49.2M
FUSN
65
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$2.08M 0.04%
659,992
– –
ACHL
66
DELISTED
Achilles Therapeutics
ACHL
$1.45M 0.03%
1,607,834
-3,406,853
-68% -$5.74M
NSTG
67
DELISTED
NanoString Technologies, Inc.
NSTG
$1.15M 0.02%
143,900
-4,458,578
-97% -$38.7M
IMUX icon
68
Immunic
IMUX
$141M
$885K 0.02%
+63,218
New +$1.72M
NAMSW icon
69
NewAmsterdam Pharma Warrant
NAMSW
$52.3M
$289K 0.01%
+333,333
New +$274K
ENTX icon
70
Entera Bio
ENTX
$495M
$216K ﹤0.01%
295,966
-1,786,406
-86% -$1.29M
ACET icon
71
Adicet Bio
ACET
$79.7M
– –
-128,711
Closed -$29.3M
BOLT icon
72
Bolt Biotherapeutics
BOLT
$7.76M
– –
-26,672
Closed -$789K
DNTH icon
73
Dianthus Therapeutics
DNTH
$5.86B
– –
-224,255
Closed -$5.06M
ENTA icon
74
Enanta Pharmaceuticals
ENTA
$358M
– –
-896,724
Closed -$46.5M
MIST icon
75
Milestone Pharmaceuticals
MIST
$115M
– –
-2,246,503
Closed -$20.6M
1 2
3
4

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, RA Capital Management held 90 positions worth $4.93B, up 5.2% from $4.69B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

RA Capital Management withdrew a net $263M in Q4 2022, closing 20 positions and reducing 10 holdings. Its most notable exit was Forma Therapeutics Holdings, Inc. Common Stock, an estimated $180M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials and Miscellaneous.

Against the trend, RA Capital Management opened a new position in Inhibrx, Inc. Common Stock worth $95M.

  • RA Capital Management's largest Q4 2022 buy was Inhibrx, Inc. Common Stock: 3,853,867 shares worth $95M.
  • RA Capital Management added most to Vor Biopharma in Q4 2022, an estimated $57.5M increase.
  • RA Capital Management's biggest Q4 2022 reduction was Biogen, cutting an estimated $114M.
  • RA Capital Management fully exited Forma Therapeutics Holdings, Inc. Common Stock in Q4 2022, selling an estimated $180M.
  • RA Capital Management's ten largest holdings make up 51% of its $4.93B portfolio in Q4 2022.
  • RA Capital Management opened 9 new positions and closed 20 in Q4 2022.
  • RA Capital Management's portfolio value rose 5.2% quarter-over-quarter to $4.93B.

Based on RA Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.